Citable filing context
ABT's research view summarizes recent SEC filing context, starting with earnings from Jul 16, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 16, 2026 | earnings | Abbott reported Q2 2026 results with $12.59 billion in sales and raised full-year adjusted EPS guidance. |
| Apr 27, 2026 | management_change | Abbott appointed Kevin Conroy to its Board of Directors and increased the board size to thirteen. |
| Apr 17, 2026 | legal_settlement | Abbott received preliminary court approval for a settlement in shareholder derivative lawsuits, including governance reforms. |
| Jul 16, 2026 | Guidance: adjusted_diluted_eps | 1.38 to 1.46 |
| Jul 16, 2026 | Guidance: adjusted_diluted_eps | 5.45 to 5.60 |
| Jul 16, 2026 | Guidance: comparable_sales_growth | 6.50 to 7.50 |
| Jul 28, 2026 | mda_quarterly | Abbott Laboratories reported a 12.2% increase in second-quarter 2026 net sales, excluding foreign exchange impacts, driven primarily by the $20.6 billion acquisition of Exact Sciences. This transaction, which established Abbott’s presence in the cancer diagnostics market, added $1.0 billion in sales through June 30, 2026, and was financed through $20.0 billion in new long-term debt. Performance across segments was mixed. Medical Devices maintained strong momentum with 8.0% growth in the first half of 2026, led by double-digit gains in Electrophysiology, Rhythm Management, and Heart Failure, alongside continued expansion of the FreeStyle Libre continuous glucose monitoring system. Conversely, Nutritional Products faced a 5.6% decline, hampered by lower volumes in U.S. pediatric and global adult portfolios. Diagnostic Products saw a 22.4% surge, bolstered by the Exact Sciences integration, which offset a decline in Rapid and Molecular Diagnostics due to a weaker respiratory virus season. Operating margins were pressured by higher intangible amortization and integration costs related to the Exact Sciences acquisition. Abbott continues to navigate significant tax litigation, including ongoing disputes with the IRS regarding income reallocation for 2017–2020 and a tax assessment from Malaysian authorities, though management maintains that these matters will not have a material adverse effect on long-term financial stability. |
| Apr 29, 2026 | mda_quarterly | Abbott's net sales increased 7.8% to $11.164 billion in Q1 2026, or 3.8% excluding favorable foreign exchange, while net earnings declined to $1.077 billion. The quarter was significantly shaped by the $20.6 billion acquisition of Exact Sciences, funded primarily by $20 billion in new long-term debt, establishing Abbott's position in cancer diagnostics with products like Cologuard®. This acquisition contributed $96 million to the Diagnostic Products segment, which also saw Core Laboratory growth on the Alinity® platform, offsetting a decline in Rapid and Molecular Diagnostics due to lower respiratory test demand. Medical Devices led growth, up 8.1% excluding foreign exchange, driven by double-digit increases in Rhythm Management (Aveir® pacemakers), Electrophysiology (ablation catheters), and Heart Failure (ventricular assist devices), alongside strong Diabetes Care sales (CGM systems). Established Pharmaceutical Products grew 9.0% ex-FX, primarily in Key Emerging Markets. Nutritional Products sales decreased 7.7% ex-FX due to lower volumes. Operating expenses rose, with SG&A up 22.2% due to Exact Sciences integration costs. The company faces significant tax disputes with the IRS (over $1 billion) and a $413 million Malaysian tax assessment, which it intends to vigorously defend. Cash and equivalents decreased to $6.8 billion due to the acquisition and debt repayment, while long-term debt significantly increased. Abbott maintains an investment-grade rating and increased its quarterly dividend by 6.8%. |
Source: SEC EDGAR filing text and events; period Jul 16, 2026; filed Jul 16, 2026.
ABT company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.